KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Construction in Progress (2017 - 2018)

Alnylam Pharmaceuticals' Construction in Progress history spans 6 years, with the latest figure at $261.0 million for Q4 2018.

  • For Q4 2018, Construction in Progress rose 95.27% year-over-year to $261.0 million; the TTM value through Dec 2018 reached $261.0 million, up 95.27%, while the annual FY2018 figure was $261.0 million, 95.27% up from the prior year.
  • Construction in Progress reached $261.0 million in Q4 2018 per ALNY's latest filing, up from $133.6 million in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $261.0 million in Q4 2018 to a low of $1.3 million in Q4 2015.
  • Average Construction in Progress over 4 years is $99.5 million, with a median of $67.8 million recorded in 2014.
  • Peak YoY movement for Construction in Progress: surged 6978.57% in 2014, then crashed 35.17% in 2015.
  • A 4-year view of Construction in Progress shows it stood at $2.0 million in 2014, then plummeted by 35.17% to $1.3 million in 2015, then soared by 10300.39% to $133.6 million in 2017, then surged by 95.27% to $261.0 million in 2018.
  • Per Business Quant, the three most recent readings for ALNY's Construction in Progress are $261.0 million (Q4 2018), $133.6 million (Q4 2017), and $1.3 million (Q4 2015).